Home > Insider Trading > Filing (0001209191-13-031139)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1571498	Epizyme Inc.	EPZM	Pharmaceutical Preparations (2834)	261349956

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1110780	Carl Goldfischer	11 Belvedere Ave Belvedere CA 94920		Yes	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2013-06-05	3,426,762	$0.00	3,426,762	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2013-06-05	65,301	$0.00	3,492,063	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2013-06-05	163,549	$15.00	3,655,612	No	4	P	Indirect	See Footnote
Common Stock	Acquisiton	2013-06-05	3,117	$15.00	3,658,729	No	4	P	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	P	Indirect	See Footnote
No	4	P	Indirect	See Footnote

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series B Preferred Stock	Disposition	2013-06-05	10,280,288	$0.00	3,426,762	$0.00
Common Stock	Series B Preferred Stock	Disposition	2013-06-05	195,904	$0.00	65,301	$0.00
Common Stock	Stock Option (right to buy)	Acquisiton	2013-06-05	17,666	$0.00	17,666	$25.73

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0		No	4	C	Indirect
0		No	4	C	Indirect
17,666	2023-06-04	No	4	A	Direct

Footnotes

Each share of Series B Preferred Stock was automatically converted into 1/3rd of a share of Common Stock upon the closing of the Issuer's initial public offering without payment of consideration.
Represents shares held by Bay City Capital Fund V, L.P. ("Fund V"); and indirect interests of Bay City Capital LLC ("BCC"), the manager of Bay City Capital Management V LLC ("Management V"), and Management V, the general partner of Fund V. Dr. Goldfischer is Managing Director of BCC. Dr. Goldfischer, BCC and Management V each disclaims beneficial ownership in such shares, except to the extent of their pecuniary interest therein.
Represents shares held by Bay City Capital Fund V Co-Investment Fund, L.P. ("Co-Investment V"); and indirect interests of BCC, the manager of Management V, and Management V, the general partner of Co-Investment V. Dr. Goldfischer is Managing Director of BCC. Dr. Goldfischer, BCC and Management V each disclaims beneficial ownership in such shares, except to the extent of their pecuniary interest therein.
Not applicable.
Vests in full upon the earlier of (i) the expiration of the Dr. Goldfischer's initial term of office as a director of the Issuer, scheduled to occur on the 2015 annual meeting of the Issuer's stockholders and (ii) June 30, 2015. In the event of a change in control of the Issuer, the vesting schedule of the option will accelerate in full.